The antifungal pipeline for invasive fungal diseases: what does the future hold?

Neoh, Chin Fen; Jeong, Wirawan; Kong, David C M; Slavin, Monica A

doi:10.1080/14787210.2023.2203383

Cited by 14 publications

(9 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, the utilization of cyclic peptides as antifungal agents holds significant promise, and there is a growing interest in exploring their therapeutic applications. Cyclic peptides offer several advantages over conventional antifungal agents, including high potency, low toxicity, and target specificity, as shown by caspofungin, micafungin, and anidulafungin [ 19 , 20 , 23 ], and the FDA recently approved Rezafungin [ 70 ] (a novel echinocandin antifungal agent against invasive candidiasis and candidemia ). Given the success of these drugs, further exploration of other cyclic antifungal peptides is warranted.…”

Section: Future Perspectivesmentioning

confidence: 99%

Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Plants, and Synthetic Sources

Helmy

Parang

2023

Pharmaceuticals

View full text Add to dashboard Cite

Fungal infections remain a significant concern for human health. The emergence of microbial resistance, the improper use of antimicrobial drugs, and the need for fewer toxic antifungal treatments in immunocompromised patients have sparked substantial interest in antifungal research. Cyclic peptides, classified as antifungal peptides, have been in development as potential antifungal agents since 1948. In recent years, there has been growing attention from the scientific community to explore cyclic peptides as a promising strategy for combating antifungal infections caused by pathogenic fungi. The identification of antifungal cyclic peptides from various sources has been possible due to the widespread interest in peptide research in recent decades. It is increasingly important to evaluate narrow- to broad-spectrum antifungal activity and the mode of action of synthetic and natural cyclic peptides for both synthesized and extracted peptides. This short review aims to highlight some of the antifungal cyclic peptides isolated from bacteria, fungi, and plants. This brief review is not intended to present an exhaustive catalog of all known antifungal cyclic peptides but rather seeks to showcase selected cyclic peptides with antifungal properties that have been isolated from bacteria, fungi, plants, and synthetic sources. The addition of commercially available cyclic antifungal peptides serves to corroborate the notion that cyclic peptides can serve as a valuable source for the development of antifungal drugs. Additionally, this review discusses the potential future of utilizing combinations of antifungal peptides from different sources. The review underscores the need for the further exploration of the novel antifungal therapeutic applications of these abundant and diverse cyclic peptides.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Plants, and Synthetic Sources

Helmy

Parang

2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Cyclic peptides offer several advantages over conventional antifungal agents, including high potency, low toxicity, and target specificity as shown with caspofungin, micafungin and anidulafungin [19,20,23]. Recently FDA approved Rezafungin [69] (a novel echinocandin antifungal agent against invasive candidiasis and candidemia. Given the success of these drugs, further exploration of other cyclic antifungal peptides is warranted.…”

Section: Future Perspectivesmentioning

confidence: 99%

Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Natural Products, and Synthetic Sources

Helmy¹,

Parang²

2023

Preprint

View full text Add to dashboard Cite

Fungal infections pose a significant threat to human health, particularly in immunocompromised individuals. Due to several factors, such as the inappropriate use of antimicrobial drugs, the emergence of resistance in microorganisms, and increasing demand for less cytotoxic antifungal agents for immunocompromised patients, antifungal research has gained significant attention in recent years. Antifungal peptides, and among them, cyclic peptides, are a class of antifungal agents that have been under development since the 1960s. Using cyclic peptides as a promising approach for combating antifungal resistance in pathogenic fungi has gained significant attention in recent years. The identification of antifungal cyclic peptides from various sources has been possible due to the widespread interest in peptide research in recent decades. It is increasingly important to evaluate the narrow to broad-spectrum antifungal activity and the mode of action of synthetic and natural cyclic peptides for both synthesized and extracted peptides. This short review aims to highlight some of the antifungal cyclic peptides isolated from bacteria, fungi, and plants, taking into consideration the progress made in peptide research. Additionally, it provides a summary of synthetic cyclic peptides with antifungal activity and discusses the potential future of utilizing combinations of antifungal peptides from different sources. The review underscores the need for further exploration of the novel therapeutic applications of these abundant and diverse cyclic peptides.

show abstract

“…Due to the increased emergence of A. fumigatus azole-resistant mutants 2 , new alternatives are necessary to treat aspergillosis. A recent addition to the antifungal repertoire is the triterpenoid ibrexafungerp (IBX), a semi-synthetic derivative of enfumafungin 3,4 . IBX binds to the 1,3-β-D-glucan synthase, the same target of echinocandins, but in contrast to this class of compounds, it has oral bioavailability 3,4 .…”

Section: Introductionmentioning

confidence: 99%

“…A recent addition to the antifungal repertoire is the triterpenoid ibrexafungerp (IBX), a semi-synthetic derivative of enfumafungin 3,4 . IBX binds to the 1,3-β-D-glucan synthase, the same target of echinocandins, but in contrast to this class of compounds, it has oral bioavailability 3,4 . Currently, IBX is approved as an oral drug for the treatment of vulvovaginal candidiasis, and it is in the process of approval against invasive candidiasis and aspergillosis [3][4][5] .…”

Section: Introductionmentioning

confidence: 99%

Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungusAspergillus fumigatus

dos Reis,

Diehl,

Pinzan

et al. 2024

Preprint

View full text Add to dashboard Cite

Aspergillus fumigatusis the primary etiological agent of aspergillosis. Here, we show that the host defense peptide mimetic, brilacidin (BRI) can potentiate ibrexafungerp (IBX) against clinical isolates ofA. fumigatusCAS-resistant strains with mutations infks1that encodes the 1,3-β-D-glucan synthase are not IBX-resistant and BRI+IBX can inhibit their growth. The combination of BRI+IBX plays a fungicidal role, increases the fungal cell permeability and decreases the fungal survival in the presence of A549 epithelial cells.

show abstract

The antifungal pipeline for invasive fungal diseases: what does the future hold?

Cited by 14 publications

References 106 publications

Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Plants, and Synthetic Sources

Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Plants, and Synthetic Sources

Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Natural Products, and Synthetic Sources

Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungusAspergillus fumigatus

Contact Info

Product

Resources

About